ARCHIVES

Study: CYP2D6 Genotypes Are Unreliable Predictors of Benefit

This article is from The Cancer Letter archive.

Vol. 35 No. 3 | March 30, 2012

Download PDF Visit The Full Archive

Related Articles

FDA Approves Imaging Agent For Recurrent Prostate Cancer

September 28, 2012

Wyngaarden says NCI’s Special Authorities Are All Right With Him

May 14, 1982

Obituary: Ellen Tobin, Consultant, Championed Patients’ Needs;

January 10, 2003

Building Boom of Proton Beam Centers Flares Up in Washington and Baltimore

October 25, 2013

President’s Budget Request for FDA Omits Funding for Critical Path.

February 8, 2008

New Center Plan Discussed By NAB, Directors Committees

May 4, 1990